Dr. Lal PathLabs Approves Q2 Results, ₹5 Dividend, Director Appointment

Dr. Lal PathLabs Ltd announced its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The Board of Directors also declared a second interim dividend of INR 5 per equity share for the financial year 2026-27, with a record date of November 11, 2026. Additionally, Ms. Vasuta Agarwal was appointed as an Additional Director (Non-Executive Independent Director) for a three-year term, subject to shareholder approval. The company also approved a further investment of up to INR 49.5 Crores in its wholly-owned subsidiary, Dr. Lal PathLabs FZCO (LPL Dubai), to support its business and operational needs, including further investment in its subsidiary Sunshine Healthcare Limited (SHL), Ghana. The Board meeting commenced at 11:49 AM IST and concluded at 01:20 PM IST.